{"summary": "Author argues Novo Nordisk's valuation implies the market is pricing its entire GLP1 revenue stream at zero, making shares attractive below $40.", "reason": "The author provides a fundamental valuation argument based on P/S ratios and market pricing of the GLP1 franchise to support a long thesis.", "ideas": [{"symbol": "NVO", "direction": "long", "thesis": "The author argues that subtracting all of Novo's GLP1 revenue (~50% of 2025 revenue) leaves ~$24B revenue, giving a P/S of 6.2x at the current $44 price, roughly in line with Novo's historical 4.5-9x P/S range. This implies the market is valuing the entire GLP1 franchise at zero, so buying now effectively gets the GLP1 revenue stream for free. The author sees upside if the obesity market grows even with margin pressure, and considers at or below $40 a no-brainer buy. Main risk acknowledged is that GLP1 revenue could contract significantly and P/S ignores the net income hit if GLP1 revenue went to zero.", "thesis_short": "Market prices Novo GLP1 revenue at zero", "quote": "if you bought Novo now at $44 a share it seems like you're getting their entire GLP1 revenue stream for free", "confidence": 0.8, "sentiment": 0.7, "timeframe": "unspecified"}], "model": "gemini-3.1-flash-lite", "verified": true, "extraction_model": "deepseek-v4-flash"}
This Reddit post, published September 10, 2026, features u/JuanPabloElTres discussing NVO. 1 trade idea extracted by AI with direction and confidence scoring.
Speakers: u/JuanPabloElTres · Tickers: NVO